KAKrasimir Antonov

Krasimir Antonov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Krasimir Antonov has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    MicroRNAs as Diagnostic Biomarkers for Liver Fibrosis in Chronic Hepatitis B: Insights from Expression Profiling and Correlations with Fibrosis Stages

    by Ventseslav Yordanov, Victoria Spasova, Diana Stefanova-Petrova, Radoslava Tsrancheva, Blaga Rukova, Desislava Nesheva, Savina Hadjidekova, Krasimir Antonov, Vesela Karamisheva, Ventsislava Pencheva

    Chronic hepatitis B (CHB) infection remains a significant global health challenge, leading to severe liver complications such as cirrhosis and hepatocellular carcinoma (HCC), which makes accurate fibrosis assessment crucial for prognosis and treatment. This study investigated the expression levels of five miRNAs (hsa-miR-21-3p, hsa-miR-29a-3p, hsa-miR-122-3p, hsa-miR-221-3p, and hsa-miR-222-3p) in 40 CHB patients classified into mild-to-moderate (F1-F2) and severe fibrosis (F3-F4) groups using transient elastography. Quantitative PCR analysis revealed that hsa-miR-29a-3p ($$r=0.72$$, $$p<0.001$$), was upregulated, while hsa-miR-21-3p ($$r=-0.65$$, $$p<0.01$$) and hsa-miR-122-3p ($$r=-0.68$$, $$p<0.01$$,) were downregulated in severe fibrosis. Combining hsa-miR-29a-3p (AUC=0.89, 95% CI: 0.84–0.94) and hsa-miR-21-3p (AUC=0.87, 95% CI: 0.82–0.93) in a predictive model improved diagnostic accuracy. These findings highlight the potential of miRNA profiling to enhance current diagnostic algorithms. Further studies in larger cohorts are needed to validate their role in fibrosis assessment and disease monitoring.

  • Open Access

    Up-to-date Epidemiology of Chronic Hepatitis C Virus Infection among Bulgarian Patients: a Single Centre Experience

    by Christo Pentchev, Mariya Petkova, Victor Alargkof, Yana Boyanova, Donika Todovichin, Aneta Ivanova, Assen Aleksiev, Krasimir Antonov

    Epidemiological data about chronic infection with Hepatitis C virus (HCV) are limited in Bulgaria. The aim of this study was to determine the Viremic Rate and the distribution of HCV genotypes in one centre for diagnosis and treatment of chronic liver diseases. Geographic patterns of genotype distribution and associations of genotype with viral load, gender and age were investigated. Serum samples from 1731 individuals with a positive HCV Antibody Test, collected between 2016 and 2019, were analysed. HCV RNA levels were determined by HCV quantitative RNA real time polymerase chain reaction. Individuals with detectable HCV RNA further underwent HCV genotyping analysis using the Versant HCV Genotype Assay (LiPA) 2.0. The mean age of all patients was 52.9±15.3 (17–87). Among those, 54.1% were men and 45.9% women. Most patients came from the south-western region of Bulgaria (21.7%). Viral load was proven in 1385 out of 1731 individuals (VR=80%). Genotype 1 (G1) was the predominant genotype (89.8%), followed by G3 (8.5%), G2 (0.9%), G4 (0.6%) and G5 (0.1%). Among individuals with G1, infection with subtype 1b was seen in 77.4% and with subtype 1a in 22.6%. Viral load was not found to be dependent on age or gender. Viral load was higher in patients with G1 compared to G3 ($$p=0.001$$). Finally, patients with G1b were significantly older than patients with G1a ($$p<0.001$$) and G3 ($$p<0.001$$). VR in the studied population (80%) appears to be higher than the VR reported for Central Europe (73.3%). In Bulgaria, the most prevalent genotype is G1 (89.8%). This is a higher rate in comparison to the observed G1 rate in Central Europe (70%). The second most prevalent genotype is G3 (8.5%), with fewer cases identified than in Central Europe (21%).


  • Open Access

    Practice Guidelines of the Central European Hepatologic Collaboration (CEHC) on the Use of Thrombopoietin Receptor Agonists in Patients with Chronic Liver Disease Undergoing Invasive Procedures

    by Robert Flisiak, Krasimir Antonov, Pavel Drastich, Peter Jarcuska, Marina Maevskaya, Mihály Makara, Željko Puljiz, Borut Štabuc, Anca Trifan

    Background: Second-generation thrombopoietin receptor agonists (TPO-RAs) are emerging as the new standard for managing thrombocytopenia (TCP) in patients with chronic liver diseases (CLDs) undergoing scheduled procedures. However, practical guidance for their routine use in CLD patients undergoing specific invasive procedures is lacking. Methods: These practice guidelines were developed by the Initiative Group for Central European Hepatologic Collaboration (CEHC), composed of nine hepatologist/gastroenterologist experts from Central Europe. Using an adapted Delphi process, the CEHC group selected ten invasive procedures most relevant to the hepatology/gastroenterology setting in the region. Consensus recommendations for each invasive procedure are reported as a final percentage of expert panel responses. Results: A consensus was agreed that TPO-RAs should be considered for raising platelet count in CLD patients undergoing scheduled abdominal surgery, high-bleeding risk dentistry, endoscopic polypectomy, endoscopic variceal ligation, liver biopsy, liver surgery, liver transplantation and percutaneous ablation, but it was also agreed that they are less beneficial or not necessary for endoscopy without intervention and paracentesis. Conclusions: Using a modified Delphi method, experts reached an agreement for TCP management in CLD patients undergoing ten invasive procedures. These practice guidelines may help with decision making and patient management in areas where clinical evidence is absent or limited.


  • Open Access

    Inosine Pranobex (Isoprinosine) – a Potential Adjuvant in the Management of Chronic HBV Infection

    by Zahariy Krastev, Nina Nikolova, Deian Jelev, Krasimir Antonov, Lyudmila Mateva